A second AKT1 inhibitor in development, ipatasertib, is currently undergoing phase I evaluation with maintenance pertuzumab and trastuzumab in patients with HER2-positive advanced breast cancer harbouring PIK3CA mutations (NCT04253561). This evidence concerns the gene PIK3CA and breast carcinoma.